益气活血方对肝星状细胞LX-2增殖和凋亡的影响
|
摘要
目的探讨中药"复方益气活血方"(Yiqihuoxue prescription)对肝星状细胞LX-2增殖和凋亡的影响。方法体外培养肝星状细胞LX-2,浓度分别为1.125,2.228,3.31,4.37,5.41 mg/ml益气活血方作用于LX-2细胞24 h,48 h,然后用MTT比色法检测细胞的增殖情况,选取合适的益气活血药物浓度(1.125,2.228,6.432 mg/ml)用流式细胞术检测益气活血药作用24 h后对LX-2细胞凋亡的影响。结果 1MTT检测结果显示,不同浓度的益气活血方用于LX-2细胞24 h和48 h后,能够抑制LX-2细胞增殖(P<0.05),24 h抑制率随药物浓度的增加而提高。48 h时,当药物浓度达到3.31 mg/ml后,其抑制作用不随药物浓度的增加而增强(P>0.05)。2流式细胞术检测显示,益气活血方(浓度分别为1.125,2.228,6.432 mg/ml),可明显促进LX-2细胞凋亡。结论益气活血方能抑制LX-2细胞的增殖,促进LX-2细胞凋亡,其抑制作用呈时间-剂量依赖性。
Objective To investigate the effect of Chinese herbal compound Yiqihuoxue prescription on the proliferation and apoptosis of LX-2 cells. Methods LX-2 cells were treated with different concentrations of Yiqihuoxue prescription(1.125,2. 228,3. 31,4. 37,5. 41 mg / ml) for 24 h and 48 h,and then the cell proliferation was measured by MTT. Then the cell apoptosis was detected at 24 h by flow cytometry in an appropriate drug concentration(1. 125,2. 228,6. 432 mg / ml). Results 1Cell proliferation was dramatically inhibited by Yiqihuoxue prescription(1. 125,2. 228,3. 31,4. 37,5. 41 mg / ml) at 24 h and 48 h( P < 0. 05). 2Yiqihuoxue prescription promoted the apoptosis of LX-2 cells at 1. 125,2. 228,6. 432 mg / ml. Conclusion Yiqihuoxue prescription can inhibit the proliferationand accelerate the apoptosis in LX-2 cells.
Objective To investigate the effect of Chinese herbal compound Yiqihuoxue prescription on the proliferation and apoptosis of LX-2 cells. Methods LX-2 cells were treated with different concentrations of Yiqihuoxue prescription(1.125,2. 228,3. 31,4. 37,5. 41 mg / ml) for 24 h and 48 h,and then the cell proliferation was measured by MTT. Then the cell apoptosis was detected at 24 h by flow cytometry in an appropriate drug concentration(1. 125,2. 228,6. 432 mg / ml). Results 1Cell proliferation was dramatically inhibited by Yiqihuoxue prescription(1. 125,2. 228,3. 31,4. 37,5. 41 mg / ml) at 24 h and 48 h( P < 0. 05). 2Yiqihuoxue prescription promoted the apoptosis of LX-2 cells at 1. 125,2. 228,6. 432 mg / ml. Conclusion Yiqihuoxue prescription can inhibit the proliferationand accelerate the apoptosis in LX-2 cells.
引文
[1]陈启明,陈青锋.肝星状细胞在肝细胞癌形成和发展中的作用[J].临床肝胆病杂志,2014,30(3):285-288.
[2]于建国,白薇,刘福义.肝纤维化与肝硬化[J].临床军医杂志,2004,32(1):102-103.
[3]范慧宁,陈尼维.肝纤维化的流行病学研究进展[J].国际消化病杂志,2014,34(1):29-31.
[4]Farazi PA,Depinho RA.Hepatocellular carcinoma pathogenesis:from genes to environment[J].Nat Rev Cancer,2006,6(9):674-687.
[5]郑瑾,刘强,史恒军,等.肝纤维化及β-榄香烯抗肝纤维化研究进展[J].山西医科大学学报,2010,41(11):935-938.
[6]夏海珊,陈少茹,钟月春,等.肝纤维化的发病机制和药物治疗现况[J].中国医药导报,2014,11(18):162-165.
[7]Xu L,Hui AY,Albanis E,et al.Human hepatic stellate cell lines,LX-1 and LX-2:new tools for analysis of hepatic fibrosis[J].Gut,2005,54(1):142-151.
[8]Henderson NC,Mackinnon AC,Farnworth SL,et al.Galectin-3 regulates myofibroblast activation and hepatic fibrosis[J].Proc Natl Acad Sci U S A,2006,103(13):5060-5065.
[9]Friedman SL.Liver fibrosis——from bench to bedside[J].J Hepatol,2003,38 Suppl 1:S38-S53.
[10]张莉,蔚红华.扶正化瘀中药治疗肝纤维化大鼠的实验研究[J].现代中西医结合杂志,2011,20(1):24-25.
[11]郝立然,李娜,李海玲,等.复方中药治疗慢性病毒性肝炎肝纤维化的Meta分析[J].临床医药实践,2011,20(7):494-497.
[12]马力天,任秦有,白杨,等.丹参联合β-榄香烯对肝星形细胞LX-2增殖和凋亡的影响[J].现代生物医学进展,2013,13(34):6626-6629.
[13]白玉,冷静.肝星形细胞及相关细胞因子IFN、TNF在肝纤维化形成中的作用[J].医学综述,2009,15(3):392-394.
[14]萧瑶,宋后燕.肝星形细胞在肝纤维化发生及治疗中的作用[J].生命的化学,2005,25(5):391-393.
[15]张良登,孙晓红,魏玮,等.肝纤维化中医理论源流[J].世界中西医结合杂志,2014,9(3):300-304.
[16]王中甫,宋素华,王玉中,等.慢性肝炎肝纤维化的中医症状聚类及分期[J].世界华人消化杂志,2010,18(11):1157-1162.
[17]姬成伟,刘晋敏,李亮成,等.川芎嗪阻抑大鼠肝纤维化作用实验研究[J].山西医科大学学报,2003,34(4):293-295.
[18]李霞,李亮成.丹参与维拉帕米对大鼠肝纤维化、肝硬化防治作用的实验研究[J].山西医科大学学报,2003,34(1):18-21.
[19]李益忠,刘旭东,黄彬.行气活血饮治疗慢性乙型肝炎肝纤维化42例[J].吉林中医药,2005,25(7):28.
[20]刘绍能,姚乃礼,殷海波,等.芪术颗粒对大鼠肝纤维化模型的治疗作用[J].中药新药与临床药理,2002,13(4):216-218.
[2]于建国,白薇,刘福义.肝纤维化与肝硬化[J].临床军医杂志,2004,32(1):102-103.
[3]范慧宁,陈尼维.肝纤维化的流行病学研究进展[J].国际消化病杂志,2014,34(1):29-31.
[4]Farazi PA,Depinho RA.Hepatocellular carcinoma pathogenesis:from genes to environment[J].Nat Rev Cancer,2006,6(9):674-687.
[5]郑瑾,刘强,史恒军,等.肝纤维化及β-榄香烯抗肝纤维化研究进展[J].山西医科大学学报,2010,41(11):935-938.
[6]夏海珊,陈少茹,钟月春,等.肝纤维化的发病机制和药物治疗现况[J].中国医药导报,2014,11(18):162-165.
[7]Xu L,Hui AY,Albanis E,et al.Human hepatic stellate cell lines,LX-1 and LX-2:new tools for analysis of hepatic fibrosis[J].Gut,2005,54(1):142-151.
[8]Henderson NC,Mackinnon AC,Farnworth SL,et al.Galectin-3 regulates myofibroblast activation and hepatic fibrosis[J].Proc Natl Acad Sci U S A,2006,103(13):5060-5065.
[9]Friedman SL.Liver fibrosis——from bench to bedside[J].J Hepatol,2003,38 Suppl 1:S38-S53.
[10]张莉,蔚红华.扶正化瘀中药治疗肝纤维化大鼠的实验研究[J].现代中西医结合杂志,2011,20(1):24-25.
[11]郝立然,李娜,李海玲,等.复方中药治疗慢性病毒性肝炎肝纤维化的Meta分析[J].临床医药实践,2011,20(7):494-497.
[12]马力天,任秦有,白杨,等.丹参联合β-榄香烯对肝星形细胞LX-2增殖和凋亡的影响[J].现代生物医学进展,2013,13(34):6626-6629.
[13]白玉,冷静.肝星形细胞及相关细胞因子IFN、TNF在肝纤维化形成中的作用[J].医学综述,2009,15(3):392-394.
[14]萧瑶,宋后燕.肝星形细胞在肝纤维化发生及治疗中的作用[J].生命的化学,2005,25(5):391-393.
[15]张良登,孙晓红,魏玮,等.肝纤维化中医理论源流[J].世界中西医结合杂志,2014,9(3):300-304.
[16]王中甫,宋素华,王玉中,等.慢性肝炎肝纤维化的中医症状聚类及分期[J].世界华人消化杂志,2010,18(11):1157-1162.
[17]姬成伟,刘晋敏,李亮成,等.川芎嗪阻抑大鼠肝纤维化作用实验研究[J].山西医科大学学报,2003,34(4):293-295.
[18]李霞,李亮成.丹参与维拉帕米对大鼠肝纤维化、肝硬化防治作用的实验研究[J].山西医科大学学报,2003,34(1):18-21.
[19]李益忠,刘旭东,黄彬.行气活血饮治疗慢性乙型肝炎肝纤维化42例[J].吉林中医药,2005,25(7):28.
[20]刘绍能,姚乃礼,殷海波,等.芪术颗粒对大鼠肝纤维化模型的治疗作用[J].中药新药与临床药理,2002,13(4):216-218.